Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease

Introduction Inflammatory arthritis encompasses a range of immune-mediated joint disorders such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), which lead to chronic joint damage and systemic complications. Despite advancements…

0 Comments

End of content

No more pages to load